Brian Krause Ph.d., Faha

Biography

Dr. Brian Krause, Ph.D., FAHA was Co-Founder and Chief Scientific Officer of AlphaCore Pharma LLC. Dr. Krause joined Parke-Davis/Pfizer where he became the lead pharmacologist on the team that discovered Lipitor and head of the ACAT team that discovered avasimibe. He served as an Executive Director of Discovery at Pfizer Inc. He was the preclinical pharmacologist on the Clinical development Team for apoAIMilano (ETC-216). His major research focus since 1973 has been cardiovascular therapeutics, in particular, cholesterol-lowering and anti-atherosclerotic drugs. He served as Senior Vice President of Preclinical Research & Discovery of Esperion Therapeutics Inc. since February 2003, after serving as Senior Vice President, Preclinical Research and Development since January 2002 and as Vice President, Development Pharmacology since March 2001. He also served as Head of Research. Prior to joining Esperion, Dr. Krause was a Research Fellow within the Cardiovascular Therapeutics Division of Pfizer Global Research, a publicly-held company, where he also served as Chair of the Dyslipidemia Team and Group Leader of the Lipoprotein Metabolism Section. Prior to the merger of Pfizer Inc. and Warner-Lambert Company in 2000, Dr. Krause was a scientist at the Parke-Davis Research Division of Warner-Lambert Company, a publicly-held company, since 1982. He serves as a Member of Scientific Advisory Board at Gemphire Therapeutics Inc. He authored or co-authored more than 100 peer reviewed scientific papers and book chapters in the field of lipoprotein metabolism and atherosclerosis. He was an NIH-sponsored post-doctorate fellow with Paul Roheim, M.D., and is a member of the American Heart Association’s Council on Arteriosclerosis, Thrombosis and Vascular Biology. Dr. Krause received a B.S. in Biological Sciences from the University of Illinois Medical Center in Chicago and a Ph.D. in Physiology from LSU Medical Center in New Orleans.

Research Interest

Cardiovascular Diseases & Diagnosis